Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

RCT (n=656) found that benralizumab reduced the exacerbation rate vs placebo over 24 weeks (RR 0.51, 95%CI 0.39-0.65). It also significantly improved the St George's Respiratory Questionnaire Score vs placebo (difference -8.11, p≤0.0001).

The Lancet Respiratory Medicine